This Study is Being Performed to Evaluate the Effect of Genasense on the Efficacy and the Safety of Rituximab/Fludarabine Combination Treatment in Previously Untreated Subjects With Chronic Lymphocyctic Leukemia(CLL)

Inclusion Criteria:

* Previously untreated subjects with intermediate-or high-risk CLL(modified Rai Stages I-IV)
* Measurable disease as primarily established by the National Cancer Institute-sponsored Working Group(NCI-WG) Guidelines for the diagnosis of CLL
* Requiring therapy for active disease, as primarily defined by the NCI-WG Guidelines
* Eastern Cooperative Oncology Group Performance Status \< 2
* Adequate organ function determined , 14 days prior to the first dose of study medication

Exclusion Criteria:

* Absolute Lymphocyte count \> 100,000/uL
* Prior chemotherapy or other therapy for CLL, including allogeneic transplant
* Less than 3 weeks from any prior major surgery at the time of informed consent
* Failure to recover from any serious adverse effect of surgery
* History of autoimmune hemolytic anemia or autoimmune thrombocytopenia
* Active serious infection requiring systemic anti-infective therapy